rosiglitazone has been researched along with gentamicin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Henney, JE | 1 |
| Cekmen, M; Ilbey, YO; Mete, F; Ozbek, E; Simsek, A; Somay, A | 1 |
2 other study(ies) available for rosiglitazone and gentamicin
| Article | Year |
|---|---|
From the Food and Drug Administration.
Topics: Diabetes Mellitus, Type 2; Endotoxemia; Gentamicins; Humans; Hypoglycemic Agents; Joint Prosthesis; Pioglitazone; Rosiglitazone; Temporomandibular Joint; Temporomandibular Joint Disorders; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 1999 |
Rosiglitazone, peroxisome proliferator receptor-gamma agonist, ameliorates gentamicin-induced nephrotoxicity in rats.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Gentamicins; Kidney; Kidney Diseases; Kidney Tubules; Male; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2010 |